Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class, derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri).
It is a cyclic heptapeptide that reversibly binds to platelets, inhibiting platelet aggregation. Eptifibatide is used to reduce the risk of acute cardiac ischemic events in patients with unstable angina or non-ST-segment-elevation myocardial infarction, often in conjunction with aspirin or clopidogrel and heparin.
The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
| Other Names | Integrilin, 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2, 5, 8, 11, 14, 22-hexaoxo-17, 18-dithia-1, 4, 7, 10, 13, 21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid, Eptifibatide (INN) |
|---|---|
| IUPAC Name | 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2, 5, 8, 11, 14, 22-hexaoxo-17, 18-dithia-1, 4, 7, 10, 13, 21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid |
| CAS | 148031-34-9 |
| Molecular Weight | 832 |
| Molecular Formula | C35H49N11O9S2 |
| SMILES | C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N |